Collegium Pharmaceutical (COLL) executive compensation, 2026 proxy

Vikram Karnani, President and Chief Executive Officer, was paid $1.7M in 2025, down 84% from $10.8M the year before. The CEO-to-median-employee pay ratio was 8:1, on median employee pay of $221,391.

Filed
April 7, 2026
Annual meeting
May 14, 2026
Pay year
2025
Named executives
6
CEO total pay
$1.7M-84% vs prior year
CEO to median employee
8:1median $221,391
Prior say-on-pay support
91%of votes cast
CEO Total Compensation
$1,715,846For fiscal year 2025
CEO Pay Ratio
8:1Compared to median employee
Median Employee Pay
$221,391Annual total compensation
Product Revenues
$780.6MUp 23.6% year-over-year
Share Repurchases
$25.0MReturned to shareholders

How Karnani was paid

$1.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary51%Non-equity incentive49%All other compensation0%

Named executive officers

ExecutiveTotal
Vikram KarnaniPresident and Chief Executive Officer$1,715,846
Colleen TupperExecutive Vice President and Chief Financial Officer$3,515,055
David DieterExecutive Vice President and General Counsel$3,870,092
Scott DreyerExecutive Vice President and Chief Commercial Officer$3,041,212
Thomas Smith, M.D.Executive Vice President and Chief Medical Officer$2,446,008
Shirley KuhlmannFormer Executive Vice President, Chief Administrative Officer, General Counsel and Secretary$2,783,583

What changed and why

  • $1.7MCEO Vikram Karnani received a total compensation of $1,715,846 for fiscal year 2025.
  • $780.6MNet product revenues reached $780.6 million, representing a 23.6% year-over-year increase from 2024.
  • $148.9MJornay PM net revenues grew 48% year-over-year to $148.9 million in its first full year of ownership.
  • $25.0MThe company returned $25.0 million to shareholders through its share repurchase program in 2025.
  • 91%The annual say-on-pay advisory vote received approximately 91% support from shareholders.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.